Prenetics Global Reports Explosive IM8 Growth, Strategic Divestitures, and $40M Share Repurchase Program

summarizeSummary

Prenetics Global announced a major strategic shift to consumer health, driven by its IM8 brand's explosive growth, significant non-dilutive divestitures, and a substantial share repurchase program, alongside positive FY2026 guidance.

check_boxKey Events

• Explosive IM8 Brand Growth

  IM8, the flagship consumer health brand, generated $60.1 million in revenue in its first full fiscal year (FY2025), a 16,156% increase year-over-year, and achieved $120 million in annualized recurring revenue (ARR) by December 2025. Total revenue from continuing operations increased by 480% to $92.4 million in FY2025.

• Strategic Divestitures Generate Non-Dilutive Capital

  The company completed the divestiture of ACT Genomics in October 2025 for up to $72 million (approximately $46 million gross to Prenetics) and fully divested its 35% equity stake in Insighta in February 2026 for $70 million in cash. The Europa 3PL business was also divested in January 2026 for up to $13 million in stock, streamlining operations and generating significant non-dilutive capital.

• New $40 Million Share Repurchase Program

  A share repurchase program of up to $40 million was authorized in March 2026, with $17.2 million already repurchased as of April 29, 2026, reflecting management's belief that shares are trading below intrinsic value. This follows approximately $2.75 million in open market purchases by the executive team in Q4 2025 and Q1 2026.

• Positive FY2026 Guidance and Path to Profitability

  The company provided FY2026 guidance for IM8 revenue of $180 million to $200 million and projected adjusted EBITDA profitability by Q4 2027, indicating a strong outlook for its focused consumer health business.

auto_awesomeAnalysis

Prenetics Global has undergone a significant strategic transformation, shifting its core focus from genomic testing to consumer health and longevity, primarily driven by its flagship IM8 brand. The company reported exceptional growth in IM8 revenue, which surged by over 16,000% in FY2025, contributing to a 480% increase in total revenue from continuing operations. This strategic pivot was supported by substantial non-dilutive capital generation through the divestiture of non-core assets, including ACT Genomics ($46M cash) and Insighta ($70M cash), totaling $116 million. Furthermore, the company authorized a $40 million share repurchase program, with $17.2 million already executed, signaling strong management confidence. The report also provides positive FY2026 guidance for IM8 revenue and a clear path to adjusted EBITDA profitability by Q4 2027. The confirmation of HFCAA compliance for FY2025 removes a significant regulatory overhang. These combined factors indicate a fundamental shift in the company's business model and financial trajectory, with strong positive implications for investors.